Comparative <i>In Vitro</i> Study of Various α<sub>2</sub>-Adrenoreceptor Agonist Drugs for Ticagrelor Reversal
Ticagrelor, an antiplatelet adenosine diphosphate (ADP)-P2Y<sub>12</sub> receptor antagonist, increases the risk of bleeding. Its management is challenging because platelet transfusion is ineffective and no specific antidote is currently available. Epinephrine, a vasopressor catecholamin...
Main Authors: | Guillaume Porta Bonete, Anne Godier, Pascale Gaussem, Tiphaine Belleville-Rolland, Alexandre Leuci, Sonia Poirault-Chassac, Christilla Bachelot-Loza, Anne-Céline Martin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-03-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/3/809 |
Similar Items
-
P2Y<sub>12</sub> Inhibition beyond Thrombosis: Effects on Inflammation
by: Alexandre Mansour, et al.
Published: (2020-02-01) -
Ticagrelor
by: Gianluca Airoldi, et al.
Published: (2013-03-01) -
Ticagrelor versus clopidogrel in the management of acute myocardial infarction
by: Candice Volney, et al.
Published: (2019-07-01) -
No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
by: Viviana Laredo, et al.
Published: (2020-05-01) -
Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial
by: Sarah Baos, et al.
Published: (2017-11-01)